Skip to content

Trial · Interventional

CompletedPhase 1Registry data

To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

NCTNCT06808802 (opens ClinicalTrials.gov in a new tab)Other id27303Other idJ1I-MC-GZQE
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 1
Enrollment
30 participants (actual)
Sponsor
Eli Lilly and Company · Industry
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

Singapore

Start
3 Feb 2025
Primary completion
15 Apr 2025
Completion
15 Apr 2025
First posted
5 Feb 2025
Last update posted
5 Jun 2025
Conditions
Healthy

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20252026
  1. Ph 1

    To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

    NCT06808802

    3 Feb 2025 to 15 Apr 2025

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.

Interventions

  • RetatrutideDrug
  • MetoprololDrug

Arms1

  • Experimental

    Retatrutide

    In period 1, participants will be administered a singe oral dose of metoprolol followed by a 1-week washout before retatrutide subcutaneous (SC) injection is given in period 2, followed by a second dose of metoprolol.

Primary outcomes4

Outcomes the sponsor listed as primary.

  1. Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol

    Time frame · Day 1 to Day 3

    Registry description

    PK: AUC (0-∞) of Metoprolol

  2. Pharmacokinetics (PK): AUC (0-∞) of Metoprolol with Retatrutide

    Time frame · Day 9 to Day 11

    Registry description

    PK: AUC (0-∞) of Metoprolol with Retatrutide

  3. PK: Maximum Concentration (Cmax) of Metoprolol

    Time frame · Day 1 to Day 3

    Registry description

    PK: Cmax of Metoprolol

  4. PK: Cmax of Metoprolol with Retatrutide

    Time frame · Day 9 to Day 11

    Registry description

    PK: Cmax of Metoprolol with Retatrutide

Secondary outcomes(1)

  1. Number of Participants with an Incidence of Treatment Emergent Adverse Events TEAEs (TEAEs)

    Time frame · Baseline to Day 44

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 21 Years up to 65 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and vital signs * Have a body mass index (BMI) within the range 22.0 to 35.0 kilogram per square meter (kg/m2) (inclusive) at screening Exclusion Criteria: * Have history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form), or have glycated hemoglobin (HbA1c) greater than or equal to (≥) 6.5% (48 millimole/mole (mmol/mol) * Have a mean supine screening pulse rate of less than 45 or greater than 100 beats per minute (bpm) from 2 assessments. If a repeat measurement (mean of 2 assessments) shows values within the range of 45 to 100 bpm, the participant may be included in the trial * Have significant history of or current cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data * Had any of the following cardiovascular conditions prior to screening: acute myocardial infarction, cerebrovascular accident, unstable angina, or hospitalization due to congestive heart failure

PepBank is a research reference. Talk to a doctor before you use any peptide.